Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines by Cheung, ALM et al.
Title Oncogenic mutation profiling in new lung cancer andmesothelioma cell lines
Author(s)
Lam, CLD; LUO, SY; Deng, W; Kwan, JSH; Rodriguez-Canales, J;
Cheung, ALM; Cheng, GHW; Lin, CH; Wistuba, II; Sham, PC;
Wan, TSK; Tsao, GSW
Citation OncoTargets and Therapy, 2015, v. 8, p. 195-209
Issued Date 2015
URL http://hdl.handle.net/10722/208199
Rights Creative Commons: Attribution 3.0 Hong Kong License
© 2015 Lam et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
OncoTargets and Therapy 2015:8 195–209
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
195
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OTT.S71242
Oncogenic mutation profiling in new lung cancer 
and mesothelioma cell lines
David cl lam1
susan Y luo1
Wen Deng2
Johnny sh Kwan3
Jaime rodriguez-canales4
annie lM cheung5
grace hW cheng6
chi-ho lin6
ignacio i Wistuba4
Pak c sham6
Thomas sK Wan7
sai-Wah Tsao5
1Department of Medicine, 2school of 
nursing, 3Department of Psychiatry, 
University of hong Kong, hong 
Kong sar, People’s republic of 
china; 4Department of Translational 
Molecular Pathology, MD anderson 
cancer center, University of Texas 
at houston, houston, TX, Usa; 
5Department of anatomy, 6center for 
genome sciences, 7Department of 
Pathology, University of hong Kong, 
hong Kong sar, People’s republic of 
china
correspondence: David cl lam 
Department of Medicine, University  
of hong Kong, Queen Mary hospital,  
102 Pokfulam road, hong Kong,  
People’s republic of china 
Tel +852 2255 4455 
Fax +852 2816 2863 
email dcllam@hku.hk
Background: Thoracic tumor, especially lung cancer, ranks as the top cancer mortality in most 
parts of the world. Lung adenocarcinoma is the predominant subtype and there is increasing 
knowledge on therapeutic molecular targets, namely EGFR, ALK, KRAS, and ROS1, among lung 
cancers. Lung cancer cell lines established with known clinical characteristics and molecular 
profiling of oncogenic targets like ALK or KRAS could be useful tools for understanding the 
biology of known molecular targets as well as for drug testing and screening.
Materials and methods: Five new cancer cell lines were established from pleural fluid or 
biopsy tissues obtained from Chinese patients with primary lung adenocarcinomas or malignant 
pleural mesothelioma. They were characterized by immunohistochemistry, growth kinetics, tests 
for tumorigenicity, EGFR and KRAS gene mutations, ALK gene rearrangement and OncoSeq 
mutation profiling. 
Results: These newly established lung adenocarcinoma and mesothelioma cell lines were main-
tained for over 100 passages and demonstrated morphological and immunohistochemical features 
as well as growth kinetics of tumor cell lines. One of these new cell lines bears  EML4-ALK 
rearrangement variant 2, two lung cancer cell lines bear different KRAS mutations at codon 12, 
and known single nucleotide polymorphism variants were identified in these cell lines.
Discussion: Four new lung adenocarcinoma and one mesothelioma cell lines were established 
from patients with different clinical characteristics and oncogenic mutation profiles. These 
characterized cell lines and their mutation profiles will provide resources for exploration of lung 
cancer and mesothelioma biology with regard to the presence of known oncogenic mutations.
Keywords: lung adenocarcinomas, oncogenic mutations, EGFR, ALK, KRAS
Introduction
Despite knowledge on known therapeutic targets like epidermal growth factor receptor 
(EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangement, and 
continuous efforts in clinical trials, lung cancer remains the top cause of cancer mor-
bidity and mortality in most parts of the world.1,2 Lung adenocarcinomas arising from 
female nonsmokers have emerged as a prominent subgroup among lung cancer patients, 
especially in Asia, compared to lung cancer arising from smokers and squamous cell 
carcinoma as in the past.3,4 Oncogenic driver mutations have been identified and they are 
present in mutually exclusive ways in individual lung tumors. These oncogenic mutations 
include EGFR, KRas (KRAS), ALK, MET, etc.5 Some of these oncogenic mutations pos-
sess therapeutic implications for being the targets of actions for small molecule tyrosine 
kinase inhibitors (TKI).6 Even with the presence of these molecular targets, however, 
there are mutant tumors that do not respond to the corresponding targeted agents, or 
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mutant tumors that do respond initially followed subsequently 
by development of resistance to the corresponding targeted 
agents. A better understanding of the mechanisms of actions 
of these therapeutic oncogenic driver mutations in lung cancer 
may allow for identification of new molecular targets for better 
diagnostics and targeted therapy of lung cancer.
We have previously reported the establishment of lung can-
cer cell lines with known clinical properties like sex, smoking 
habits, and ethnicity.7 In this study, we have further established 
five new cell lines with four being adenocarcinomas and one 
being a malignant pleural mesothelioma (MPM) cell line. 
They carry different molecular properties and together with 
the four published before, represent the heterogeneity of 
thoracic tumors.7 The aim of this study was to establish and 
to characterize new cancer cell lines from Chinese patients 
with known clinical characteristics, tumor staging, prior 
therapy, and known oncogenic mutation profiles so that these 
new lung cancers and mesotheliomas could provide defined 
materials for research in lung cancer and mesothelioma. 
The morphological and growth kinetics properties as well 
as oncogenic driver mutation status of the cell lines were 
described. Mutation profiling was performed to document 
the single nucleotide polymorphism (SNP) variants of these 
newly established lung cancer and MPM cell lines.
Materials and methods
Method of culture, medium,  
and supplement
All clinical specimens were collected after informed written 
consents had been given by the respective subjects. The study 
was approved by the University of Hong Kong/Hong Kong 
Hospital Authority Hong Kong West Cluster Institutional 
Review Board/Ethics Committee (UW 11 – 326).
Pleural effusions were all obtained with aseptic tech-
niques and centrifuged to collect malignant cells. For the 
patient with mesothelioma, tumor deposits on pleura were 
biopsied under direct vision through flexirigid pleuroscopy. 
The pieces of fresh pleural biopsy were minced with pairs 
of fine scissors under aseptic conditions. Collected tissue or 
cancer cells were seeded into two different culture media, 
namely, ACL4 or RPMI supplemented with 10% fetal bovine 
serum, in order to maximize the chance of establishment. 
ACL4 medium was prepared according to the protocol pub-
lished by Oie et al.8 Penicillin and Streptomycin (105 U) were 
added as antibiotic prophylaxis for the first passage and both 
were omitted from the culture medium recipe from the second 
passage onwards. The cells were then incubated in 37°C and 
5% carbon dioxide. Attached cells reaching confluent density 
were subcultured and growth was maintained in either ACL4 
or RPMI medium.
growth kinetics study
In studying the growth kinetics of these newly established cell 
lines, 105 cells of each cell line were seeded into 25-cm2 cul-
ture flasks with 5 mL of growth medium. Cells were counted 
on days 1, 2, 4, 6, 8, 10, and 12 on triplicate flasks.
Test for tumorigenicity in nude mice
Tumor cells were harvested and counted with supravital 
staining. At least 2×105 cells were resuspended in 0.5 mL 
of growth medium. The whole cell suspension was then 
injected beneath the dorsal skin of two nude mice. The mice 
were maintained and observed for up to 6 months for any 
development of xenograft tumor. Xenografts were harvested 
before they reached an external diameter of 1 cm. The har-
vested xenografts were fixed in 4% formalin and were then 
processed into paraffin blocks with tissue sections cut and 
examined to confirm the presence of tumor xenograft as 
well as analyzed for their morphological characteristics. If 
no obvious tumor development was observed at the end of 
6 months, the corresponding mice were sacrificed and dis-
sected to look for tumor involvement in internal organs by 
gross and microscopic examination. For those lines with no 
xenograft development, a gradation of inoculums containing 
2×106, 2×107, and 2×108 tumor cells were performed further 
on two separate mice for each inoculum dosage.
Morphological characteristics  
and immunohistochemical studies
For each newly established cell line, cultured tumor cells were 
centrifuged, fixed, and embedded into paraffin cell blocks 
according to routine cytology procedures. The cultured cells 
and xenografts were characterized for their morphological 
characteristics by routine hematoxylin and eosin stain, mucin 
content, and immunohistochemistry with a panel of monoclonal 
antibodies against cytokeratins (CK7 [M7018; DAKO {Agi-
lent Technologies, Santa Clara, CA, USA}], CK20 [M7019; 
DAKO]) and the thyroid transcription factor TTF-1 (M3575; 
DAKO). All cell lines were subjected to DNA fingerprinting 
with markers STR D11S922, D11S4099, and D11S4152.
epidermal growth factor receptor (EGFR) 
mutation at exons 18–21 and KRAS 
mutation detection
Genomic DNA was extracted from freshly harvested cells, and 
extracted DNA was analyzed for mutations in exons 18–21 of 
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the EGFR gene and codons 12, 13, and 61 of the KRAS gene by 
direct sequencing according to previous protocol.9 The meth-
ods and primers used for polymerase chain reaction (PCR)-
based sequencing detection were described elsewhere.9
ALK rearrangement and variant detection
The Vysis ALK FISH dual color break apart rearrangement 
probe (Abbott Vysis 05J89-001; Abbott Laboratories, Abbott 
Park, IL, USA) was applied according to manufacturer’s 
instructions. The FISH detection was performed on unstained 
 5-µm-thick paraffin-embedded formalin-fixed cytospin  sections. 
Ten microliters of ALK probe was administered to each air-dried 
slide, and the slides were then denatured at 94°C for 4 minutes, 
then hybridized overnight at 37°C in Vysis HYBrite (Abbott 
Laboratories). The sections were then mounted with 10 µL of 
VECTASHIELD mounting medium (Vector Laboratories, Inc., 
Burlingame, CA, USA) before being ready for examination and 
scoring of results. Scoring of FISH study results were performed 
with Leica DMR fluorescence  microscope (Leica Microsys-
tems, Wetzlar, Germany). The FISH signals were evaluated by 
TSKW who was blinded to the nature of the cell lines. At least 
100 nonoverlapping and intact tumor nuclei were evaluated. 
The tumor cells were considered to be positive for FISH study 
when the red and green probe signals were wider apart than the 
distance of two nuclei or when the corresponding paired green 
signal was lost for any indexed red signal.
Immunohistochemistry was performed on unstained 4-µm 
paraffin-embedded cell block sections. The primary antibody 
for ALK (Thermo Fisher Scientific, Waltham, MA, USA) was 
used with a dilution of 1:500. Reverse transcription-PCR 
combined with direct sequencing of the PCR products were 
performed for any cell line with ALK rearrangement with 
FISH to identify EML4-ALK variants.10
Karyotyping
Metaphase preparation
To accumulate metaphases, cells were treated with colcemid 
(Sigma-Aldrich Co, St Louis, MO, USA; 0.03 mg/mL) for 
3 hours. Chromosome spreads were prepared as previously 
described.11 Slides with cells in metaphase were left for 
aging at room temperature for up to 7 days prior to spectral 
karyotyping (SKY) procedures.
sKY
The slides were treated with DNase-free RNase solution 
(0.1 mg/mL) at 37°C for 1 hour. After washing in 2X SSC for 
10 minutes, the slides were dehydrated successively in 70%, 
85%, and 95% ethanol at room temperature for 2 minutes each, 
and were then air-dried with nitrogen gas. The slides were 
treated with proteinase K solution (0.02 µg/mL) at 37°C for 
15 minutes and washed in 2X SSC for 10 minutes. The slides 
were then fixed in 2% paraformaldehyde and were washed in 2X 
SSC for 10 minutes each, followed by successive dehydration 
again in 70%, 85%, and 95% ethanol for 2 minutes. The slides 
were placed in 70% formamide/2X SSC at 80°C for 4 minutes 
and again were successively dehydrated in 70%, 85%, and 95% 
ethanol for 2 minutes each. The SKY probes (SkyPaintTM mix-
ture; Applied Spectral Imaging, Migdal HaEmek, Israel), after 
prior denaturation at 80°C for 7 minutes and being placed at 
37°C for 1 hour in a water bath, were then applied to denatured 
slides, which were then covered by coverslips, followed by seal-
ing rubber cement and then were further incubated at 37°C for 
more than 36 hours in a humidified chamber. The recommenda-
tions of the SKY probe manufacturer were followed for SKY 
signal detection. SKY image capturing and karyotyping were 
performed using the SkyVision Imaging System equipped with 
a Zeiss Axioplan 2 fluorescence microscope (Zeiss Germany, 
Jena, Germany). Twenty-five to thirty metaphases from each 
cell line were analyzed using SKY. Karyotypes were analyzed 
using international nomenclature system.12
Oncogenic molecular profiling with 
rainDance Oncoseq analysis
Three micrograms of genomic DNA was extracted from each 
cell line and optical density was measured with 260/280 
ratio to be 1.8 or more before proceeding with further tests. 
The RainDance OncoSeq predesigned panel (RainDance 
Technologies, Inc., Lexington, KY, USA) used, which cov-
ered 142 oncogenes and included downstream Solexa next-
generation sequencing with a coverage depth of 200×. The 
FastQC package v0.11.2 was used to assess the read quality. 
Filtered read sequences were mapped to the human reference 
genome (hg19) with Burrows–Wheeler Alignment v0.7.9a,13 
and PCR as well as optical duplicates were marked using 
Picard v1.105. Variants were called using FreeBayes v0.9.1414 
with a quality score cutoff of $30 and a minimum coverage 
of ten per sample. Variant annotation was performed with 
ANNOVAR15 using GALAXY16 and functional predictions 
were conducted using SIFT17,18 and PROVEAN.19
Results
clinicopathological features  
of the patients from which cell  
lines were established (Table 1)
FA34 was grown from the malignant pleural effusion of a 
34-year-old nonsmoking lady with primary adenocarcinoma 
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Table 1 a table summarizing the clinical characteristics of patients from which these new cell lines were derived and established
Cell lines FA34 FA44 FA49 FA98 PME1
sex/age (years) Female/34 Male/58 Male/53 Male/80 Male/73
smoking habits lifetime nonsmoker chronic smoker chronic smoker chronic smoker ex-smoker
Tissue origin Pleural fluid Pleural fluid Pleural fluid Pleural fluid Pleural fluid
Tumor cell type adenocarcinoma adenocarcinoma adenocarcinoma adenocarcinoma Malignant pleural mesothelioma
staging iV iV iV iV iV
Prior treatment Paclitaxel, pemetrexed,  
cisplatinum, erlotinib
Paclitaxel,  
carboplatin
Paclitaxel,  
carboplatin
empirical  
erlotinib
no treatment prior to 
collection of biopsy specimen  
Tumorigenicity in nude mice Yes Yes Yes Yes no
Potential oncogenic  
mutations
EML4-ALK  
translocation variant 2
KRAS mutation at 
codon 12 (g215T)
KRAS mutation at  
codon 12 (g219a)
EGFR and KRAS  
wild type
of the right lower lobe (T3N2M1b). She presented with 
pleural effusion and had tried multiple lines of systemic 
chemotherapy, including paclitaxel, pemetrexed, and TKI 
treatment (despite the fact that she was known to have EGFR 
wild type lung tumor). Computerized tomography (CT) of 
thorax and abdomen showed no other tumor site. The patient 
passed away in 2008 with progressive disease despite dif-
ferent lines of drug therapy, but the cultured cells continue 
to proliferate to beyond the 100th passage, and it was only 
after the patient passed away that EML4-ALK translocation 
became known to be present in up to 7% of non-small cell 
lung cancer.20 The established line was tested to harbor 
 EML4-ALK translocation with variant type 2 of exon 20: 
exon 20 rearrangement (Table 1).
FA44 came from the pleural fluid of a 58-year-old male 
chronic smoker who presented with right pleural effusion 
with confirmed malignant pleural effusion with metastatic 
 adenocarcinoma. CT scan revealed a contrast-enhancing tumor 
in the right lower lobe and metastatic nodules in the right 
middle and left lower lobes of the lungs. There was no other 
mass lesion in the liver, spleen, or kidneys. The patient had 
received paclitaxel/carboplatin for six cycles with subsequent 
stable disease maintained for 5 months. He subsequently went 
into progressive disease with increasing recurrent right pleural 
effusion and enlargement of the primary tumor as shown on CT 
scan. Pleural fluid was obtained on this disease progression. 
His general condition deteriorated quickly and did not allow 
time for consideration of salvage chemotherapy.
FA49 was also taken from the pleural fluid of a  53-year-old 
chronic smoker who was diagnosed to have stage IV adeno-
carcinoma of lung with primary tumor in the right lower 
lobe. He also received paclitaxel and carboplatin for six 
cycles with partial response maintained for 3 months after 
chemotherapy, followed by progressive disease with enlarge-
ment of primary tumor, increasing right pleural effusion, 
and development of new cervical lymphadenopathy. 
The right pleural fluid was obtained with therapeutic 
pleurocentesis at that juncture.
FA98 was cultured from an 80-year-old male chronic 
smoker presented with right pleural effusion and CT find-
ing of a right hilar mass with right upper lobe collapse. The 
patient opted for, because of his age, upfront EGFR-TKI 
and not chemotherapy despite the fact that EGFR mutation 
status was not known for him at the time of diagnosis. The 
patient was started on erlotinib and he decided to maintain 
it despite the fact that EGFR mutation tests came back to 
show no mutation subsequently. His general condition con-
tinued to deteriorate with rapid accumulation of right pleural 
effusion requiring multiple pleurocentesis, where aspirated 
pleural fluid was saved for culture. He finally succumbed 
after 4 weeks of empirical erlotinib.
PME1 was derived from a 73-year-old man who had 
retired from incinerator service with exposure to asbestos; 
he presented with right pleural effusion and nodular thick-
ening of right pleura and ascites. CT scan revealed bilateral 
nodular pleural thickening, right pleural effusion, and ascites. 
Repeated diagnostic pleural tapping only showed atypical 
cells not diagnostic of malignant effusion. Flexirigid pleuro-
scopy was performed with pleural biopsy taken, which con-
firmed on both light and electronic microscopy to be MPM. 
The patient received six cycles of pemetrexed and cisplatin 
with stable disease maintained for the subsequent 7 months, 
after which the disease progressed with increasing bilateral 
pleural effusion and ascites and he finally succumbed.
FA34, FA44, FA49, and FA98 were derived from pleu-
ral fluid adenocarcinoma cells taken from patients who 
had received prior treatment with either platinum-based 
chemotherapy (for FA34, FA44, and FA49) or empirical 
EGFR-TKI treatment (for FA98) before EGFR mutation 
status was known. PME1 was taken from patient alongside 
diagnostic pleuroscopy and thus mesothelioma cells were 
treatment-naïve.
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cell culture characteristics  
and authentication
All cell lines were maintained for over 100 passages. 
The five cell lines demonstrated different morphological 
properties. All the cell lines demonstrated tightly packed 
attached cells that tended to pile up before reaching 
confluency (Figure 1). This feature might be related to 
the formation of cell clusters in these cell lines before 
 spreading to form confluent tumor cell layers. FA44, FA49, 
FA98, and PME1 showed fairly uniform  populations of 
Figure 1 Photomicrographs showing morphological and immunohistochemical properties of different cell lines.
Notes: side-by-side photomicrographs at 40× and 200× magnification, respectively, for each of FA34 (A and B), Fa44 (C and D), Fa49 (E and F), Fa98 (G and H), and 
PMe1 (I and J) cell lines. 
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cells while FA34 showed slightly more variation in tumor 
cell size.
All the lung adenocarcinoma cell lines were stained 
positive for CK7 but stained negative for CK20, which is 
the typical immunohistochemical profile for carcinoma 
of pulmonary origin. The lung adenocarcinoma cell lines 
were also all positive for CK7 and TTF1, and negative for 
CK20 (Figure 2). Napsin A was stained positive for FA44 
but negative for other lung adenocarcinoma cell lines in this 
report (Figure 3). PME1 was also stained positive for anti-
vimentin A and B but negative for mucin, WT1, and calretinin 
(Figure 4), which again suggested mesothelial origin. All the 
cell lines showed different fragments on DNA fingerprinting 
with markers STR D11S922, D11S4099, and D11S4152.
growth kinetic study
FA44, FA49, FA98, and PME1 showed a short lag phase 
of up to 2 days. FA98 grew faster than others (Figure 5). 
FA34 showed an initial lag phase of around 5 days followed 
by a more accelerated phase (Figure 5). FA44, FA49, FA98, 
and PME1 showed similar doubling times of about 22 hours; 
FA34 showed a doubling time of around 34 hours.
Test for tumorigenicity in nude mice
All adenocarcinoma cell lines, FA34, FA44, FA49, and 
FA98, formed xenografts of 1 cm in about 6–8 weeks after 
subcutaneous inoculation of 106 cells onto the back of a nude 
mouse for each cell line. The xenografts obtained from these 
cell inoculations could result in tumors again after retrans-
plantation (passaging) into separate nude mice. The time for 
xenograft detection was 3–4 weeks after injection (when a 
subcutaneous bulge became visible), and by 6–8 weeks after 
inoculation the xenograft would reach the external dimension 
of 1 cm for xenograft harvesting. PME1 failed to produce any 
xenograft at 12 weeks after tumor cell injection with at least 
three separate attempts for each dose of tumor cell injection. 
A FA34, TTF1 positive  B FA44, TTF1 positive 
C   FA49, TTF1 positive D FA98, TTF1 positive 
E FA34, CK7 positive  F FA44, CK7 positive 
Figure 2 (Continued)
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Figure 3 Immunohistochemical staining with Napsin A on paraffin cell blocks for all 
the four lung adenocarcinoma cell lines.
Notes: (A) Fa34, (B) Fa44, (C) Fa49, and (D) Fa98.
Figure 2 Immunohistochemical staining with TTF1, CK7, and CK20 on paraffin cell blocks for all four lung adenocarcinoma cell lines. 
Notes: (A–D) TTF1 positive staining for each cell line, (E–H) cK7 positive staining for each line, and (I–L) cK20 negative staining for each line.
I FA34, CK20 negative J FA44, CK20 negative 
K FA49, CK20 negative L FA98, CK20 negative 
G FA49, CK7 positive  H FA98, CK7 positive 
Xenografts obtained from FA34, FA44, FA49, and FA98 
were sectioned and reviewed, and they all showed xenografts 
predominantly containing the inoculated tumor cells.
EGFR and KRAS mutation status
All of the cell lines were tested wild type for EGFR mutation 
at exons 18–21. FA44 and FA49 were both KRAS mutations 
at codon 12 with G215T and G219A, respectively. No KRAS 
mutation was found at codons 12, 13, or 61 in FA34, FA98, 
and PME1.
ALK rearrangement and variant detection
FISH for ALK rearrangement were tested for all these 
new cell lines, with FA34 showing ALK rearrange-
ment (Figure 6) according to standard scoring criteria 
OncoTargets and Therapy 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
202
lam et al
Figure 4 Immunohistochemical staining on paraffin cell blocks from PME1.
Notes: staining with (A) anti-vimentin a, (B) anti-vimentin b, (C) mucin negative, (D) anti-cK a, (E) anti-cK b, (F) calretinin negative, and (G) WT1 negative.
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Figure 5 growth curves of all the cell lines showing the initial lag phase followed by accelerated growth phase in most cell lines with Fa44, Fa49, and Fa98 showing the 
fastest growth rate compared to Fa34 and PMe1.
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Figure 6 ALK immunohistochemistry and Fish.
Notes: (A) Paraffin cell block section of FA34 showed positive ALK immunohistochemical staining; (B) ALK rearrangement with Fish for Fa34; and (C) Fa44 as a control 
showing no ALK rearrangement with Fish.
while all the others showed no ALK rearrangement. ALK 
immunohistochemical staining for sections from FA34 
cytospin cell blocks also showed strong positive staining 
when compared to other cell lines and the kit control. Reverse 
transcription PCR showed transcripts compatible with E20: 
A20 translocation, ie, EML4-ALK variant 2.
Karyotypes of the cell lines  
analyzed using sKY
We analyzed the karyotypes of the cancer cell lines at late pas-
sages (greater than passage 50) using SKY (Figure 7). All of 
these newly established lung cancer cell lines showed  specific 
clonal chromosomal aberrations (Table 2). Numerically, 
FA34b is  near-tetraploid; FA44a, FA49, FA98, and PME1 
are  near-triploid.
Oncogenic molecular profiling
Out of 142 cancer genes profiled with RainDance OncoSeq, 
42 gene variants representing variants in 27 genes were iden-
tified in different cell lines (Table 3). With the SIFT17,18 and 
PROVEAN19 softwares, detected variants were predicted to 
have damaging/deleterious or tolerated/neutral effects on the 
resulting protein structure or functions. We also examined 
the list for mutations that had been reported in the COSMIC 
database (v69).
Two STK11/P variants (serine/threonine kinase 11 
interacting protein, NM_052902: exon15: c.G1687A: 
p.V563I) with predicted deleterious effects were found in 
FA34 and FA44. BLM (Bloom syndrome, RecQ helicase-
like, NM_000057: exon11: c.C2371T: p.R791C), RECQL4 
(NM_004260: exon5: c.G1060A: p.V354I), and ERBB2 
Figure 7 (Continued)
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Figure 7 spectral karyotyping images of all the cell lines.
Notes: (A) Fa34; (B) Fa44; (C) Fa49; (D) Fa98; and (E) PMe1.
(NM_004448: exon27: c.C3508G: p.P1170A) variants were 
found in FA34 alone. An ATM variant (ATM serine/ threonine 
kinase, NM_000051:exon6:c.G566A:p.R189K) with poten-
tial deleterious effects was found in FA44, together with a 
tolerated variant of EGFR at exon 13 (NM_005228: exon13: 
c.G1562A: p.R521K), and FLT3 (fms-related tyrosine 
kinase 3, NM_004119: exon6: c.C680T: p.T227M), and 
another variant of ERBB2 was found at the same genetic 
locus as in FA34 above. A Notch1 variant (NM_017617: 
exon11: c.A1762C: p.T588P) was found in FA98. A WRN 
variant (Werner  syndrome, RecQ helicase-like, NM_000553: 
exon26: c.G3222T: p.L1074F) was found in PME1.
Discussion
The five lung adenocarcinoma and mesothelioma cell lines 
were newly established from lung cancer and mesothe-
lioma patients with advanced-stage disease, and each of 
them carries their respective oncogenic driver mutation, 
including two new lung adenocarcinoma cell lines with two 
different KRAS mutations at codon 12, and one new lung 
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Table 2 Karyotype descriptions in newly established lung cancer cells lines analyzed using spectral karyotyping
Cell lines Karyotype
FA34 90∼96,4n., XXXX, +del(X)(p1?), +del(X)(q2?), +der(X)t(X;14)(p22.3;q11)t(X;18)(q28;?), der(1)t(1;17)(p2?;?)t(14;17)(?;?), del(1)(q2?), 
del(1)(q3?), +del(2)(q14), -3, der(3)t(3;14)(p11;q?)t(3;13)(q26;q?), +der(4)t(1;4)(p11;q11)×2, +der(4)t(1;4)(?;p12)t(1;4)(q11;q13), +der(4;5)
(p10;p10), -6, +der(7)t(7;8)(p11;p11), der(8;18)(q10;p10)×2, -9, del(9)(q3?), der(9)t(9;19)(p11;p11)del(9)(q3?)×2, del(10)(p11)dup(10)(q?), 
der(10)t(1;10)(?;q26), +i(11)(q10), +der(11)t(1;11)(p11;q11), -12, der(12)t(4;12)(q?;p13)t(12;17)(q24.3;?), -13, -13, i(14)(q10), der(14)
t(11;14)(q12;p13), der(15)t(15;20)(p11;?), +der(16)t(11;16)(p11;p11), -17, +der(18)t(17;18)(q12;p11.3), -19, del(19)(p11), -21, -21[cp30]
FA44a 68∼75,3n., XXY, +dic(1;19)(p11;q13.4), +der(1)t(1;4)(p11;q11), +2, +4, der(4;5)(p10;p10), +5, +der(5)t(5;15)(q2?;q1?), -6, +der(7)
t(7;17)(q3?;q?), der(8)t(7;8)(?;q2?), +9, der(9)t(8;9)(q?;q34)dup(8)(q?), der(9)t(8;9)(?;p24)t(9;10)(q3?;q11), -10, 11, der(12)t(8;12)
(q11;p11), der(12)t(12;13)(p1?;q2?)t(8;12)(q?;q2?)dup(8)(q?), -13, -13, -15, der(10;15)(q10;q10), +der(17)t(12;17)(q?;p1?)t(12;17)(q?;?), 
del(18)(p11), der(18)t(11;18)(?;p11.3), -19, del(19)(p11), +22, der(22)t(19;22)(?;p11), der(22)t(5;22)(?;p11), der(22)t(11;22)(?;p11), i(22)
(q10)[cp27]
FA49 60∼65,3n., der(X)t(X;15)(p11;q1?)t(X;9)(q2?;p11), der(X)t(X;9)(q2?;p11), Y, +Y, der(2)t(2;14)(p1?;q2?)t(2;7)(q2?;?), +3, der(3)t(3;15)
(q11;q?)t(13;15)(q1?;q?), der(3;17)(p10;q10), der(4)t(4;20)(q11;?), i(4)(q10), +del(5)(q12)×2, der(5;15)(q10;q10), der(5)t(5;22)(q11;q?)
t(4;22)(q?;q?), der(6)t(6;20)(q27;?), der(6;11)(p10;p10), del(6)(p12), +8, der(8;11)(q10;p10), dup(8)(q?), der(8)t(8;13)(q11;q?)t(13;17)
(q?;q11), -9, der(9)t(9;12)(q11;?), +10, der(10)t(7;10)(p11;p11)×2, +12, del(12)(p11), der(12)t(12;22)(p13;q12)t(12;21)(q13;q21), -13, -13, 
der(13)t(10;13)(q12;p11)t(8;13)(q21;q13), -14, -15, der(15;18)(q10;q10), -17, del(18)(q12), -19, -20, der(20)t(7;20)(q36;q21), -21, -22, 
der(21;22)(q10;q10), der(22)t(13;22)(q21;q13)[cp25]
FA98 58∼-62,3n., XXY, i(1)(q10), -2, -3, -4, +5, -6, -7, +8, der(9;22)(q10;q10), -10, -11, -13, +15, der(15;19)(q10;p10)×2, -16, -18, -20, 
der(22)t(9;22)(q11;q13)[cp30]
PME1 68∼-74,3n., XX, -Y, del(1)(p31), der(2;19)(p10;?q10), -3, +4, der(4)t(4;9)(q2?;?)×2, der(5)t(5;18)(p15;q12), +i(6)(p10), +9, del(9)
(q12)×2, -0, der(12)t(9;12)(q11,p13), del(13)(q?), +14, der(14)t(2;14)(q22;q32)×2, +der(17)t(Y;17)(q12;q24), del(18)(q11)×2, del(19)
(p11)del(19)(q11), der(19)t(2;19)(p12;p13), -22[cp30]
 adenocarcinoma cell line with EML4-ALK translocation. 
All the new adenocarcinoma cell lines were CK7 and TTF1 
positive on immunohistochemical staining and at the same 
time CK20 negative, which is the typical immunohistochemi-
cal profile for lung adenocarcinoma. The combination of 
TTF1- and napsin A-positive staining has been shown to 
give a sensitivity of 79.2% in demonstrating cells of primary 
lung adenocarcinoma origin.21 The mesothelioma cell line 
was in addition stained positive for anti-vimentin and cal-
retinin, again the typical immunohistochemical profile for 
mesothelioma cells.
FA44 and FA98 showed a shorter initial lag phase and 
they formed confluent cell layers, while FA34 and PME1 
displayed tumor cell aggregation. The tendency for tumor 
cells to form clusters is apparently not associated with tum-
origenicity in nude mice, as all four lung adenocarcinomas 
but not the mesothelioma cell line resulted in formation of 
tumor xenografts in nude mice (Table 1).
ALK rearrangement variant 2 was found in FA34 which 
originated from a young lady, who was a nonsmoker, with 
lung adenocarcinomas with metastatic pleural effusion that 
demonstrated no response to multiple lines of systemic che-
motherapy and EGFR-TKI. At the time of presentation, crizo-
tinib was not yet available, so had not been considered. Lung 
adenocarcinoma cell lines bearing EML4-ALK rearrangement 
were seldom found in the literature and the more-commonly 
used ones were NCI-H3122 and DFCI032.22 EML4-ALK rear-
rangement was reported to be more-commonly found in young 
patients, especially nonsmokers, with lung adenocarcinoma.20 
The FA34 ALK rearranged lung adenocarcinoma cell line 
reported in this study will be useful available material for fur-
ther study of EML4-ALK translocated lung adenocarcinomas 
of Chinese origin for further study in the biology and drug 
response for EML4-ALK lung cancer.
Two different KRAS mutations at codon 12 were found in 
two lung adenocarcinoma cell lines, FA44 and FA49. These 
two cell lines were derived from male smokers, and were 
the typical subtype of lung adenocarcinomas for smokers 
who were not responsive to platinum-based chemotherapy. 
KRAS mutant lung cancer cell lines were found in the NCI-H 
series, namely H23, H358, H441, and H1792, which all bear 
codon 12 mutations.23 The two newly established lines in 
this report, FA44 and FA49, would add further available lung 
adenocarcinoma cell lines of Chinese origin for further in vitro 
study into the understanding of KRAS mutant lung cancer.
Each of the cell lines showed complex structural chro-
mosomal aberrations, yet shared no common structural 
exchanges (derivative chromosomes), indicating the complex 
nature of chromosome aberrations in cancer development. 
However, losses or partial deletions of chromosome 13 were 
observed in all five cancer cell lines. Chromosome 13 is 
known to harbor RB1, a tumor suppressor gene, the deletion 
of which may contribute to tumor growth in lung cancer.24 
The composite karyotypes (indicated by “cp” at the ends 
of descriptions) of the cell lines suggest the high levels of 
genomic instability of the cell lines.
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Oncogenic mutation profiling in new lung cancer and mesothelioma cells
Among the 42 genes with mutation or SNP identified 
from the RainDance OncoSeq panel, there were genes 
commonly found to be mutated/variant in lung cancer while 
some other mutant/variants could be the characteristics 
of individual cancer cell lines. We used the SIFT17,18 and 
PROVEAN19 softwares to predict whether these mutations 
could give rise to damaging or deleterious effects to the 
resultant expression.
Notch1 was found to be a variant in FA49, FA98, and 
PME1. Notch1 is believed to control cell proliferation 
and apoptosis. Notch1 upregulation and expression were 
found to have inhibitory effects on tumor cell growth in 
adenocarcinoma cells.25 The growth of mesothelioma cells 
has been shown to be affected by aberrant Notch1 signaling.26 
The two adenocarcinoma cell lines, FA49 and FA98, as well 
as PME1 in the mesothelioma cell line, possess variants in 
Notch1 and could be used as an in vitro model to further study 
the role of Notch1 in lung adenocarcinoma and mesothelioma 
cell growth.
STK11/P (or LKB1) was found to be mutated in all five 
cancer cell lines. LKB1 is known to be a tumor suppressor 
gene that encodes for a serine/threonine kinase, which is 
involved in the adenosine monophosphate-dependent protein 
kinase (AMPK) pathways for the regulation of intracellular 
energy level.27 Mutation or variants of LKB1 have been 
reported in genomic studies on lung cancers, and the presence 
of LKB1 mutation may cause dysregulation of these AMPK 
pathways and thus could result in disinhibition of energy-
consuming anabolic processes and eventually promote tumor 
growth.28,29 AXIN2 is another known tumor suppressor gene 
on the Wnt/β-catenin pathway and a variant (NM_004655: 
exon7: c.G1807C: p.A603P) was found in both FA34 and 
FA98. AXIN2 polymorphism was reported to be associated 
with risk of developing lung cancer, at least in Japanese30 
and Turkish groups.31
Two different ERBB2 variants were found in FA34 and 
FA44, whereas an EGFR variant was also present in FA44. 
Both EGFR and ERBB2 (also known as HER2/neu) belong 
to the same family of erbB receptor tyrosine kinases. Both 
ERBB2 gene (which encodes for HER2) and EGFR mutation 
at exons 18–21 are major proliferative drivers that activate 
downstream growth signaling pathways.32 However, the 
ERBB2 variants were found at exon 27, which differs from 
the mutations at exon 20 that have been found to correlate 
with clinical characteristics and therapeutic response;33 the 
same for EGFR mutation at exon 13 in this study, which was 
different from the usual region of mutations within exons 
18–21.32
ATM protein plays a role in the DNA damage response 
signaling pathway.34 It acts as a link between DNA damage, 
cell cycle progression, and cell death.34 FA44 was found to 
carry ATM mutation and thus could be a cell line model for 
in vitro drug testing and targeting.35
BLM and RECQL4 were found to be variants in FA34. 
Both BLM and RECQL4 encode for RecQ helicase which is 
important for the proper maintenance of telomere length.36 
IL21R (interleukin 21 receptor, NM_021798: exon4: 
c.A238C: p.T80P) was another variant found among these 
newly established cell lines. Aberrant IL21R may inter-
fere with the action of IL21, which itself could be tumor 
suppressive.37,38
A BRCA1 variant (breast cancer 1, early onset, 
NM_007297: exon9: c.A2972G: p.E991G) with potential 
deleterious effects was found in FA34 and PME1. BRCA1 
is known to be involved not only in breast cancer but also in 
lung cancer, where it has been found to be associated with 
smoking status, histological features, as well as sensitivity 
towards platinum-based chemotherapy.39
Mutations in MPM are thought to be scant, are seldom 
identified to be of significant functional implication, and are 
mostly believed to be epigenetic oncogenic changes.40,41 In 
PME1, however, we did identify WRN _ENREF_33 muta-
tions or SNP, which may represent the scant oncogenic 
genomic changes in mesothelioma.42
Although the panel of RainDance Oncoseq was limited to 
the detection of genetic variants/mutations in a panel of 140 
known oncogenic mutations, it served as a screening tool for 
potential oncogenic targets within those cancer cell lines. The 
molecular profiles identified in this study shared similarity as 
well as difference with recent molecular landscapes identified 
by next-generation sequencing. EGFR, KRAS, and STK11/P 
have been identified to be commonly variant in cytological 
specimens of lung adenocarcinomas43 and in lung adeno-
carcinoma tissue (STK11/P and ATM).44 Mutations of all 
these potential therapeutic oncology targets – namely ALK 
rearrangement, KRAS mutations, ERBB2, Notch1, BRCA1, 
BLM, and related RecQL4, IL-21R, STK11/P, and ATM – were 
reported in various frequencies in lung cancer before.45,46 This 
demonstrated the representativeness of these new lung cancer 
and mesothelioma cell lines and their potential usefulness 
for therapeutic drug testing.
In summary, we have established four new primary 
lung adenocarcinoma cell lines and one new malignant 
mesothelioma cell line from Chinese patients with different 
clinical characteristics, cell culture properties, and oncogenic 
mutation profiles. These new cancer cell lines could add 
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to the present pools of publicly available lung cancer and 
mesothelioma cell lines, the majority of which were derived 
from patients of non-Asian origin, serving as potentially use-
ful tools for functional studies and drug sensitivity testing in 
lung cancer and malignant mesothelioma.
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